Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ALC heads into its November 11 earnings date down 8% over the past month, with the lending market relaxed and short sellers showing little conviction either way.
The clearest feature of the current setup is how little pressure there is from the short side. Short interest is minimal, and availability in the lending pool is extraordinarily loose at 1,502%, meaning there are roughly fifteen shares available to borrow for every one already lent out. That is well above the 52-week low of 1,056% availability, and the direction of travel this week has been toward even more supply. Borrowing costs have picked up roughly 30% over the past week to 1.05%, but that remains firmly in ordinary territory for a Swiss large-cap. The short score has drifted lower over the past two weeks, from around 33.5 to 31.9, which points to reducing rather than building short conviction. Positioning looks relaxed rather than charged.
The stock's recent weakness is therefore a price story, not a short-seller story. ALC closed at CHF 52.68 on October 6, down 3.2% on the week and 8% over the month. Correlated peers had a mixed week: TMDX fell 4.5% and OPTOMED dropped 9.2%, while GMED and ATEC each added roughly 1%. The sector-wide weakness in ophthalmic and surgical devices appears to be doing more work here than any stock-specific catalyst. Valuation multiples have compressed alongside the price: the P/E ratio has fallen by about 1.5 points over the past 30 days to 16.5x, and EV/EBITDA has slipped to 10.8x. Those are not demanding numbers for a health-care supplies name with strong forward earnings momentum.
Factor scores tell a constructive fundamental story that the price action has so far ignored. Forward EPS growth ranks in the 85th percentile of the universe, and 30-day EPS momentum ranks in the 83rd, both pointing to an improving earnings trajectory. The dividend score is in the 99th percentile, though the dividend history on record is stale and the current yield is negligible at around 0.6%. On the other side, the EV/EBIT factor scores in the 29th percentile, flagging that on an operating-earnings basis the stock is not cheap relative to peers. Analyst data is too old to cite meaningfully, the most recent consensus information is from late 2022 and cannot be treated as current.
The alt-data picture adds a note of caution worth flagging, though neither dataset has been measured as a lead on Alcon's reported financials. CMS data shows Medicaid units reimbursed were down 38% in Q1 2026 versus the same quarter a year earlier, and Medicaid prescriptions were down 42% year on year. Both figures cover the January 2026 quarter. These datasets from the Centers for Medicare and Medicaid Services have not been shown to lead Alcon's own revenue figures, so they are colour rather than signal, but the magnitude of the declines in the government reimbursement channel is worth keeping in mind as context for the November print.
Institutional ownership is well-diversified across index and active managers, with no single holder above 4%. Walter Scott and Partners added 303,000 shares as of September 30, and UBS Asset Management added just over a million shares in the July reporting period. Invesco's last disclosed figure showed a very large addition of roughly 10 million shares as of June 30, though that figure may reflect a reclassification or portfolio restructuring rather than a fresh conviction buy. Insider activity is stale: the most recent trade on record is a modest board-level purchase of 3,000 shares in May at CHF 51.14, a price close to where the stock trades today.
With earnings on November 11, the next 35 days will test whether the compression in forward multiples reflects genuine deterioration in the business or simply a de-rating alongside broader medtech sector softness.
See the live data behind this article on ORTEX.
Open ALC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
